Epilepsy in children: quality of life and disease control

Miral A Almomani1, Basima A Almomani2, Roaa B Banikhaled1

  • 1Department of Pediatrics and Neonatology, Faculty of Medicine, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan.

Frontiers in Neurology
|December 22, 2025
PubMed

Insights

Childhood epilepsy significantly impacts quality of life (QoL). Factors like older age at diagnosis, fewer seizures, and reduced medication use improve QoL and disease control in pediatric epilepsy patients.

Area of Science:

  • Pediatric Neurology
  • Quality of Life Research
  • Epilepsy Management

Background:

  • Childhood epilepsy poses significant challenges to a child's health, quality of life (QoL), and overall development.
  • Understanding the factors influencing QoL and disease control is crucial for effective pediatric epilepsy management.

Purpose of the Study:

  • To assess health-related quality of life (HRQoL) and disease control in pediatric epilepsy patients in Jordan.
  • To identify determinants associated with higher HRQoL and better seizure control.

Main Methods:

  • A cross-sectional online survey was conducted with 178 pediatric epilepsy patients in Jordan.
  • Quality of life was assessed using the Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55).
  • Disease control was defined as being seizure-free for one year.

Main Results:

  • The mean HRQoL score was 50.74 ± 22.54, with emotional wellbeing scoring highest and physical functioning lowest.
  • Higher HRQoL was associated with older age at diagnosis, absence of comorbidities, fewer annual seizures, and reduced antiepileptic medication use.
  • Only 42.1% of patients had controlled epilepsy; disease control correlated with older age and higher QoL, while uncontrolled seizures were linked to caregiver exhaustion and polytherapy.

Conclusions:

  • Childhood epilepsy substantially diminishes children's QoL.
  • Older age at diagnosis, fewer comorbidities, reduced seizure frequency, and less medication contribute to better QoL and seizure control.
  • Interventions focusing on caregiver support and minimizing polytherapy may improve both QoL and epilepsy management in children.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
590
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.1K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
780